UCB to acquire Candid Therapeutics for $2B in immunology push

What's the deal? Belgian biopharma giant UCBDealroom has a profile for this one. Try Dealroom → is acquiring Candid Therapeutics, a San Francisco-based biotech startup, for approximately $2B. The deal gives UCB access to Candid's novel T-cell engager platform, which is designed to selectively deplete specific immune cells involved in autoimmune diseases. The acquisition expands UCB's existing immunology pipeline with a new class of therapeutics.

Why now? T-cell engagers — a technology originally developed in oncology — are gaining traction as a potential breakthrough in treating autoimmune conditions. The approach works by redirecting a patient's own T-cells to eliminate disease-causing immune cells, offering a more targeted alternative to broad immunosuppression. Several large pharma companies have been racing to secure early-stage assets in this space, making Candid a prime target.

What could go wrong? Candid's T-cell engager programmes are still in early stages of development. Paying $2B for preclinical or early-clinical assets carries significant risk — the therapies may not prove safe or effective in larger trials. UCB will also need to integrate Candid's team and technology while continuing to advance its own pipeline, a challenge that has tripped up many acquirers before.

The signal: UCB's $2B outlay for a clinical-stage company underscores how aggressively mature pharma players are moving to lock up next-generation immunology assets before they reach later-stage validation — and the premium pricing that comes with it. For UCB, a company historically anchored in neurology and immunology, the acquisition deepens its bet on targeted immune-cell depletion as a platform rather than a one-off programme.

Read more: AP News